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ABSTRACT: The bone marrow stroma consists of a heterogeneous population of cells that provide the structural and physio-
logical support for hematopoietic cells. Additionally, the bone marrow stroma contains cells with a stem-cell-like character that
allows them to differentiate into bone, cartilage, adipocytes, and hematopoietic supporting tissues. Several experimental
approaches have been used to characterize the development and functional nature of these cells in vivo and their differentiat-
ing potential In vitro. In vivo, presumptive osteogenic precursors have been identified by morphologic and immunohistochemi-
cal methods. In culture, the stromal cells can be separated from hematopoietic cells by their differential adhesion to tissue
culture plastic and their prolonged proliferative potential. In cultures generated from single-cell suspensions of marrow, bone
marrow stromal cells grow in colonies, each derived from a single precursor cell termed the colony-forming unit-fibroblast.
Culture methods have been developed to expand marrow stromal cells derived from human, mouse, and other species. Under
appropriate conditions, these cells are capable of forming new bone after in vivo transplantation. Various methods of cultiva-
tion and transplantation conditions have been studied and found to have substantial influence on the transplantation out-
come. The finding that bone marrow stromal cells can be manipulated in vitro and subsequently form bone in vivo provides a
powerful new model system for studying the basic biology of bone and for generating models for therapeutic strategies aimed
at regenerating skeletal elements,
Key words. Bone marrow stromal cells, osteoprogenitor cells, transplantation, bone regeneration.
(I) Introduction
It is now well-appreciated that marrow is a complex tis-
sue composed of two distinct but interdependent com-
partments: the hematopoietic system and the bone mar-
row stroma. Investigations into the cooperative interac-
tions between these two compartments have shown that
hematopoietic cells influence the activity of the stromal
compartment, and in addition to serving as a mechanical
support for differentiating hematopoietic cells, the bone
marrow stroma also expresses cell-signaling factors that
participate in the development of mature blood cells. A
vast body of literature concerning hematopoietic cell
transplantation exists; however, much less attention has
been paid to transplantation of bone marrow stroma.
Here, we review the development and functional nature
of bone marrow stroma, and detail studies on the trans-
plantation of bone marrow stromal cells (BMSCs) for the
regeneration of skeletal elements.
(11) The Bone Marrow Stroma in vivo
"Stroma", in ancient Greek, means the physical substrate,
or something upon which one rests or lies.
Hematopoietic cells proliferate, differentiate, and
mature upon a meshwork of cell processes and surfaces
that together comprise the bone marrow stromal scaf-
fold. In mammals, hematopoiesis is an extravascular
process, and therefore is supported by an extravascular
marrow stroma as well. The stroma includes all cell types
that (1) are located between the outer surfaces of marrow
blood vessels and the bone surfaces which encase the
hematopoietic space and tissue, and (2) are not of the
hematopoietic lineage, and these include marrow
adipocytes, Westen-Bainton cells, bone-lining cells
(inactive osteoblasts), and osteoblastic cells.
Westen-Bainton cells (Westen and Bainton, 1979;
Bianco et al., 1993) are specialized, hematopoiesis-sup-
porting cells noted for, and defined by, the expression of
high levels of membrane-associated alkaline phos-
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phatase activity, the time-honored marker of osteogenic
commitment in bone development. These cells are
referred to by a variety of descriptive terms (reticular
cells, adventitial reticular cells, and stromal fibroblasts).
The diversity in nomenclature, together with the remark-
ably elusive morphology of the cells themselves, con-
tributes to the vagueness of our concept of the marrow
stroma as a tissue. Therefore, the eponymic designation
(Westen-Bainton) and a functional phenotypic trait
(alkaline phosphatase activity, ALP) best substitute for
these terms. In the post-natal marrow, these cells pro-
vide an adventitial (outer) coating to the sinusoid wall
on which they spread with no intervening physically con-
tinuous basement membrane. Extensive, elongated, and
attenuated cell processes characterize their morphology
("reticular"). These cells express collagen types I and III,
osteonectin, and are considered "fibroblastic" in nature.
It should be noted, however, that the collagen fiber con-
tent is extremely sparse in the normal bone marrow.
In development, Westen-Bainton (WB) cells popu-
late the primitive marrow spaces prior to the local
appearance of hematopoietic cells. They originate from
the primitive osteogenic periosteum of developing
bones and co-migrate, along with ingrowing blood ves-
sels, to the interior of developing bones, where they
actively proliferate and provide the reservoir of immedi-
ate osteogenic precursors (proliferating pre-osteoblasts)
for pre-natal osteogenesis (Bianco and Bonucci, 1991;
Riminucci et al., 1997). When the primitive, non-
hematopoietic marrow is seeded with blood-borne
hematopoietic stem cells, a close relationship is estab-
lished between developing blood cells and WB (stromal)
cells. interestingly, endothelium-specific, carbohydrate-
binding receptors termed selectins are expressed in stro-
mal cells (PJ Simmons, personal communication), and
likely mediate the physical interaction between maturing
blood cells and an extravascular stroma. In the post-
natal marrow in situ, WB cells generate and maintain the
hematopoietic micro-environment. Indiscernible in rou-
tine histological material, and elusive even by electron
microscopy, WB cells can be conveniently imaged in situ
by ALP cytochemistry and confocal reflectance
microscopy (Bianco and Boyde, 1989, 1993), which
allows for documentation of their 3-D shape, mutual
arrangement, and physical association with maturing
hematopoietic cells. Their association with the adventi-
tia of small arteries and the outer surfaces of sinusoids
in the post-natal marrow reflects the developmental coup-
ling of osteogenesis and vascularity.
Several pathological conditions in the bone/bone
marrow organ can be seen as diseases of WB cells-that
is, of osteogenic marrow stromal cells. In the developing
marrow, cells identified as the major parathyroid-hor-
mone-binding cell type in vivo (Rouleau et at., 1988) are
indistinguishable from WB cells. Interestingly, bone dis-
ease in human hyperparathyroidism is characterized by
localized increases in WB cells, which result in the so-
called "endosteal fibrosis" (Bianco and Bonucci, 1991).
Likewise, in the McCune-Albright syndrome, where stim-
ulation of the relevant signal transduction pathway is
due to mutated, overactive Gsa, the fibrous dysplasia of
bone results from an increase in number of WB cells
(Riminucci et al., 1997). Weston-Bainton cells also prolif-
erate and mature to bone-forming cells responsible for
osteosclerosis in cancer metastasis to the marrow (P
Bianco, unpublished data).
In post-natal human marrow, Weston-Bainton cells
demonstrate characteristics of pre-adipocytes (Bianco et
al., 1988). A progressive decline and eventual complete
loss of ALP activity accompany their conversion to fat
cells in vivo. Adipose conversion of ALP-positive WB cells
is part of the general developmental program of the
skeleton. An inverse relationship between ALP-positive
WB cells and adipocytes can be demonstrated at any age
or marrow site (Bianco et al., 1993). Local peritrabecular
adipose conversion of WB cells occurs in involutional
osteoporosis. Thus, age-related changes in the size and
functional properties of the WB cell compartment in the
post-natal marrow represent an obvious direction for
future investigation.
As pre-osteogenic and pre-adipogenic cells, WB cells
are multipotential elements in the post-natal marrow. As
an integral part of the hematopoietic micro-environ-
ment, they are also endowed with a phenotype and func-
tion that are differentiated in their own right. This
emphasizes how retention of the potential for multiple
differentiation (a "stem cell" characteristic) may be asso-
ciated with differentiated function in the stromal system.
This represents a major biological divergence from the
hematopoietic system, from which the very concept of
the stromal system was derived by analogy.
(111) Bone Marrow Stromal Cells in vitro
To date, the identity of the in vitro counterpart of the bone
marrow stroma observed in vivo (Westen-Bainton cells) is
not entirely clear. However, when bone marrow is plated
in vitro, adherent cells of non-hematopoietic origin (i.e.,
not macrophages) proliferate and exhibit many of the
characteristics attributed to bone marrow stromal cells in
vivo (Ashton et al., 1985; Owen, 1988). In cultures generat-
ed from single-cell suspensions of marrow, colonies are
formed, each derived from a single precursor cell termed
the colony-forming-unit fibroblast (CFU-F) (Friedenstein
et al., 1978; Latsinik et al, 1986), and the progeny of these
CFU-F are what we define here as bone marrow stromal
cells (BMSCs). When marrow cells are plated at higher
densities, the colonies merge early and BMSCs grow as
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monolayers Due to a high proliferation
potential, BMSCs can be expanded in cul-
ture to greater than a billion nucleated cells
from a limited starting sample of I mL of a Bone
human bone marrow aspirate, or from the
contents of the long bones of a guinea pig, 4
rat, mouse, or rabbit (Friedenstein, 1980).
Isolation of relatively pure BMSC cultures
can be attained after subculture, however,
the degree of purification may be depen-
dent on the species and strain of animal
used. Contamination with hematopoietic
cells is higher in mouse BMSC strains than
human BMSCs, and is diminished during
consecutive passages in vitro (Krebsbach et
al, 1997; Kuznetsov et al, 1997b) In addi- Adipocytes
tion to their fibroblast-like morphology,
BMSCs share some, but not all, features
with fibroblastic cells of other tissues, and
lack the basic characteristics of endothelial Figure 1. Pleuri
cells and macrophages (Castro-Malaspina et ha de tri
al, 1980; Fei et al, 1990; Song et al, 1995; ability to form
Zhang et al, 1995). After extended culture, adipocytes. Adc
BMSCs maintain the ability to form bone, strated that the
cartilage, fibrous tissue, hematopoiesis- one type to ano
supporting reticular stroma and associated such, this populi
adipocytes, and perhaps muscle (Fig. 1). and in disease s
Thus, the BMSC population contains pre- of which was dc
cursor cells capable of extensive prolifera-
tion and differentiation into several phenotypes
(Chailakhyan et al., 1978, Ashton et al., 1980; Patt et al,
1982, Owen, 1988; Bennett et al, 1991).
Interest in BMSCs and their transplantation has
increased because of the realization that BMSC strains
can reform such a broad array of tissues. When trans-
planted under appropriate in vivo conditions, ex vivo
expanded BMSCs regenerate bone and associated stro-
mal structures and support hematopoiesis. This capacity
has obvious clinical applications, especially since an
alternative approach, induction of new bone by bone
morphogenetic protein(s), would require large amounts
of material and therefore may not be realistic in cases of
massive defects (Yoshikawa et al., 1996a).
Transplantation of BMSCs has distinct advantages
over transplantation of the total marrow cell population.
First, large numbers of BMSCs can be generated from a I
mL marrow aspirate, thus avoiding the necessity for an
additional surgery to harvest large amounts of autoge-
nous marrow. For example, marrow harvested from long
bones of a single rat provide enough cells for 2 or 3 suc-
cessful bone-forming transplants, while BMSC cultures
initiated by the same cell numbers provide enough cells
for 50 transplants (Yoshikawa et al, 1996a). Under appro-
priate conditions, BMSCs maintain their multipotential
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potent nature of bone marrow stromal cells. In vitro and in vivo studies
ted that multi-colony-derived strains of bone marrow stromal cells have the
bone, cartilage, hematopoiesis-supportive stroma, and associated
Jitionally, in certain pathological conditions, in vitro studies have demon-
phenotype expressed by a bone marrow stromal cell can be shifted from
ther, demonstrating the extremely plastic nature of this cell population. As
lation of cells is likely to play a major role in skeletal metabolism, in health
states. The background of this Fig. shows individual BMSC colonies, each
lrived from a single colony-forming-unit fibroblast.
capability during prolonged cultivation and multiple
passages in vitro, although it is true that a 'stem-cell"
character has never been definitively demonstrated (i e,
the ability to self-renew continuously). However, the out-
come of BMSC transplantation is strongly dependent on
a number of cultivation and transplantation parameters,
as well as on the BMSC species origin, as described
below. Second, bone formation by transplanted BMSCs
generally occurs more rapidly, and is more extensive
than in transplants of total marrow cells (Goshima et l.,
1991b; Gundle et al., 1995, Krzymanski and Wiktor-
ledrzeiczak, 1996).
(IV) Heterotopic Transplantation in
Diffusion Chambers
Diffusion chamber transplants have been used to test
the osteogenic potential of both non-human and human
cell sources. BMSCs can be transplanted in vivo within
diffusion chambers made of Lucite rings bounded by two
Millipore filters (0.45 mm pores) The chambers allow for
the passive diffusion of nutrients and signaling mole-
cules from the recipient, but do not elicit an immuno-
logic response The filters also prevent direct interaction
between donor and recipient cells. Therefore, no vascu-
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larization of the transplants occurs, and the tissues
formed inside the chambers are entirely of donor origin.
Although this closed system is quite useful for studying
the differentiating capacities of transplanted cell popula-
tions, it is limited by its inability to characterize the
requirements necessary to support hematopoiesis, and
to identify the cooperative cell-cell or cell-matrix interac-
tions that occur in vivo.
(A) BONE FORMATION IN DIFFUSION CHAMBERS
SEEDED WITH NON-HUMAN BMSCs
Tissues formed by rabbit BMSCs transplanted within dif-
fusion chambers are dependent on the dimensions of
the chambers. In narrow chambers (0.1 mm thick), woven
bone and fibrous tissue are formed. In wider chambers (2
mm thick), bone and fibrous tissue form on the periph-
ery, while cartilaginous tissue often develops toward the
middle of the chambers (Ashton et al., 1980, 1984;
Friedenstein et al., 1987). These results suggest that fac-
tors influencing the differentiation of multipotential
BMSCs include the diffusion of nutrients and oxygena-
tion of cells. In deeper regions of the chambers, where
diffusion of nutrients and oxygen supply would likely be
reduced, cartilage is formed, whereas osteogenesis pro-
ceeds in regions neighboring the membranes of the dif-
fusion chamber, where the surrounding vasculature con-
tributes nutrients, cell-signaling factors, and oxygen.
Rabbit BMSCs expanded in vitro for as many as 17 pas-
sages have been shown to retain their osteogenic poten-
tial (Miskarova et al., 1970). This result is not influenced
by the numbers of transplanted cells (in the range of 1 x
104 to 2 x 106 BMSCs per chamber) (Friedenstein et al.,
1987). Osteogenesis by guinea pig BMSCs is more
dependent on the initial cell number within the cham-
bers, with bone formed at high cell concentrations, but
only fibrous tissue formed at lower concentrations
(Chailakhyan and Lalykina, 1969). Neonatal pig BMSCs
implanted at high concentrations in 2-mm-thick cham-
bers consistently form bone, cartilage, and fibrous tissue
6-8 weeks after transplantation (Thomson et al., 1993),
while rat BMSCs are less osteogenic in the closed system
and form bone only in 10% of the chambers at 8-12 weeks
post-transplantation (Goshima et al., 199 lb).
(B) BONE FORMATION IN DIFFUSION CHAMBERS
SEEDED WITH HUMAN BMSCS
The osteogenic potential of human BMSCs has also been
studied in diffusion chambers implanted intraperitoneal-
ly into immunocompromised mice. Interestingly, bone
and cartilage formation was not detected 2-12 weeks
after transplantation when the cells were cultured with-
out dexamethasone (Ashton et al., 1985; Haynesworth et
al., 1992; Gundle et al., 1995). These results were not influ-
enced by age or gender of the donors, or by the anatom-
ical site from which the marrow was harvested
(Haynesworth et al., 1992). However, if human BMSCs
were cultured in the continuous presence of dexametha-
sone (10-8 M) prior to transplantation, they produced
osteogenic tissue with active osteoblasts, and cartilage
deeper into the chamber (Gundle et al., 1995).
(V) Heterotopic Transplantation
in Open Systems
To study the cooperative cell-cell and cell-matrix interac-
tions that occur in bone development and homeostasis
of the adult skeleton, investigators have transplanted
BMSCs into open systems (i.e., no barriers between
donor and host cells) such as under the kidney capsule
of syngeneic animals. Transplantation under the kidney
capsule allows the BMSCs to interact with a recipient
environment that includes a rich vascular supply. As a
result, more complex and physiologically relevant tis-
sues can be formed than in diffusion chambers. A disad-
vantage of investigating the osteogenic potential of
BMSCs in kidney capsule transplants is that in addition
to being a technically difficult surgical procedure, only
small tissue samples can be studied, and the number of
samples analyzed per recipient animal is limited. To over-
come these limitations, more recent studies have
exploited the ability of immunocompromised mice to
accept cell transplants from different strains and species
of animals in a variety of anatomical sites that allow for
multiple transplantations.
For open system transplants, the use and nature of
the transplantation vehicle clearly are essential compo-
nents for successful osteogenesis. Osteogenesis does
not proceed when bone marrow suspensions are inject-
ed subcutaneously or intramuscularly, and when BMSCs
are implanted as a cell pellet without a vehicle (Goshima
et al., 199 lb; Yoshikawa et al., 1996a), or when BMSCs are
implanted into rapidly resorbed vehicles (Friedenstein et
al., 1981; Gorsheva et al., 1981). Thus, it is evident that, in
order to form bone, transplanted BMSCs require the
presence of an organized substrate in which they can
adhere and proliferate for periods long enough to ensure
differentiation and osteogenesis. Of the vehicles used for
BMSC transplantation to date, hydroxyapatite-based
constructs have emerged as the most successful.
(A) TRANSPLANTATION OF NON-HUMAN CELLS
IN OPEN SYSTEMS
Bone formation by rat BMSCs was studied in subcuta-
neous transplants in various types of hydroxyapatite
(HA)-containing ceramics in the form of disks or cubes
including HA coralline ceramic (Yoshikawa et al., 1996a),
hydroxyapatite/tricalcium phosphate (HA/TCP)
(Goshima et al., 1991b; Dennis et al., 1992; Dennis and
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Caplan, 1993), and self-setting porous HA cement
(Yoshikawa et al., 1996b). In most transplants, extensive
bone formation developed. The histologic sequence of
events leading to osteogenesis was reminiscent of that
described during embryonic intramembranous bone for-
mation. After one week, pores of the ceramic vehicle were
filled with proliferating mesenchymal cells. At two weeks,
osteoblast-like cells lined the surface of the ceramic and
deposited small amounts of bone directly onto ceramic
surfaces. By four weeks, new bone covered most of the
pore surfaces and was followed by bone remodeling in
close association with the ingrowing vasculature. At
eight weeks, marrow cavities containing a substantial
amount of hematopoietic cells were formed in conjunc-
tion with the new bone (Goshima et al., 199 lb). Bone for-
mation started on the surface of the ceramic and
advanced toward the center of the pore (Yoshikawa et al.,
1996a). In most transplants, no cartilage was found,
though chondrocytes could be occasionally observed in
avascular pores (Goshima et al., 1991b; Dennis et al., 1992;
Dennis and Caplan, 1993). Interestingly, ceramics pre-
treated with fibronectin or laminin retained twice the
number of BMSCs than non-treated ones, and led to
more rapid osteogenesis than non-treated vehicles (2
weeks vs. 4 weeks). In addition, more transplants in
HA/TCP ceramic were positive for bone than in coral-
based ceramic (Dennis et al., 1992; Dennis and Caplan,
1993). By means of a more typical tissue engineering
strategy, it was shown that bone formation could be
accelerated if rat BMSCs were precultured within HA-
containing vehicles for two weeks prior to transplanta-
tion (Yoshikawa et al., 1996a). This approach could be
promising for clinical applications of autogenous BMSCs
and deserves further investigation for human cells.
Bone and bone marrow were formed by rat BMSCs
that were cultured for four weeks on a type I collagen
matrix prior to transplantation. In these experiments, the
cells had an opportunity to synthesize a matrix within
the vehicle. If BMSCs had been cultured on the collagen
matrix for only two days, the collagen matrix was rapidly
resorbed, no bone formed after transplantation, and fat
tissue developed instead (Mizuno et al., 1997). These data
emphasize that, for successful bone formation by BMSCs
that have been cultured in vitro, the transplanted vehicle
should be sustained in vivo for at least several weeks to
allow for adequate proliferation and differentiation nec-
essary for the initiation of osteogenesis. If the vehicle is
resorbed prior to these events, such as is the case for cer-
tain types of collagen matrices, bone formation will not
ensue. Some success with resorbable vehicles has been
reported for transplants of rat BMSCs in poly(DL-lactic-
co-glycolic acid) foam. After a one-week in vitro culture
period in which rat BMSCs were able to proliferate and
establish an extracellular matrix within poly(DL-lactic-
co-glycolic acid) foams, transplants were placed into the
rat mesentery (Ishaug-Riley et al., 1997). Ectopic bone
was formed as early as one week post-transplantation;
however, the mineralized tissue penetrated only about
200 to 400 microns into the polymer implant. Considered
collectively, these data suggest that the successful use of
rapidly resorbing vehicles may require an in vitro growth
period to allow BMSCs to organize an extracellular
matrix so that a BMSC network primed for osteogenesis
will be implanted.
Mouse BMSCs have been transplanted in collagen
sponges under the kidney capsule of syngeneic recipi-
ents. Ossicles containing bone marrow were developed
in most transplants by 4-5 weeks, and they were main-
tained for at least five months (Grosheva et al., 1981;
Friedenstein et al., 1982; Kuznetsov et al., 1989). When
mouse BMSCs were transplanted subcutaneously into
immunocompromised recipients, they formed bone
complete with hematopoietic tissue in all vehicles test-
ed: collagen sponges, collagen matrices, polyvinyl
sponges, HA/TCP blocks, and HA/TCP powder
(Krebsbach et al., 1997). In collagen sponges, the new
bone appeared as early as two weeks post-transplanta-
tion. At four weeks, a cortical-like bone capsule devel-
oped surrounding an area with active hematopoiesis.
The bone marrow tissue included reticular and adipocyt-
ic stroma, and hematopoietic cells of all lineages and
stages of maturation, including colony-forming cells, in
numbers equivalent to those of skeletal marrow. Both
bone and hematopoietic tissue showed no signs of
degeneration or senescence for at least 14 weeks post-
transplantation (Krebsbach et al., 1997) and, thus, could
be considered self-maintained.
Rabbit BMSCs were transplanted autogenously
under the kidney capsule inside Plexiglas rings.
Heterotopic ossicles were formed in all 45-90-day-old
transplants. Interestingly, the nature of the associated
marrow tissue mirrored the original bone marrow from
which BMSC cultures had been initiated. BMSCs cul-
tured from cellular (red) marrow produced a stroma with
numerous hematopoietic foci, whereas those cultured
from a hypocellular (yellow) marrow produced a stroma
replete with fat cells (Patt et al., 1982). These important
data imply that rabbit BMSCs "remember" their origin
during numerous passages in vitro and after in vivo
implantation, and recreate the structure of their original
tissue. it would be interesting to study whether the same
phenomenon can be demonstrated for BMSCs of other
species, including human.
In open system transplants, however, it is necessary
to determine the origin (donor vs. recipient) of tissues
formed, since it is conceivable that transplanted cells
could induce undifferentiated mesenchymal cells pres-
ent at the site of transplantation to form bone. Studies
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Figure 2. Demonstration of the formation of a bone/bone marrow ectopic ossicle by transplanted bone marrow stromal cells. (a) When
ex vivo expanded human bone marrow stromal cells are attached to ceramic particles or CollagraftT as a vehicle (V) and transplanted
into a subcutaneous site in immunocompromised mice, ectopic bone (B) is formed within 4-6 weeks. (b) This ectopic ossicle exhibits exten-
sive bone formation (B) by osteoblastic cells in close association with the vehicle particles (V). (c) Further, complete hematopoiesis (HP)
including megakaryocytes (M) and adipocytes (A) is supported in close association with the newly formed bone (B).
using chromosomal markers, mouse strain-specific anti-
serum, species-specific antibodies, and reverse trans-
plantation have shown that in heterotopic transplants of
either rodent marrow cells or BMSCs, bone-forming cells
are of donor origin. By similar criteria, hematopoietic
cells and macrophages originate from the recipient
(Friedenstein et al., 1968, 1978; Hotta et al., 1983) In
transplants of BMSCs derived from transgenic mice bear-
ing a type collagen-chloramphenicol acetyltransferase
(CAT) reporter gene, cells within the newly formed bone
displayed CAT activity up to at least 14 weeks post-trans-
plantation (Krebsbach et al., 1997), providing yet another
method to follow the fate of the transplanted cells In
one report, transplants of quail marrow into nude mice
showed a biphasic switch in the origin of new bone-form-
ing cells (Goshima etal., 1991a) Afterthree to four weeks
in vivo, osteocytes were of donor origin, but were later
identified to be of host origin by eight to 12 weeks post-
transplantation, by means of a specific nuclear marker.
Although this switch in the origin of bone-forming cells
has not been observed with rodent or human cells, it is
certainly conceivable that as the newly formed tissue
matures, mesenchymal cells of recipient origin in the
microenvironment of the transplant may be induced to
differentiate into functional osteoblasts.
(B) TRANSPLANTATION OF HUMAN CELLS
Human BMSCs transplanted subcutaneously into
immunocompromised mice in HA or HA/TCP ceramic
blocks (in the form of disks or cubes) consistently formed
bone four to eight weeks post-transplantation Bone was
deposited directly in apposition to the ceramic surface
and developed from the surface toward the center of the
pores, At 6-8 weeks, bone remodeling and formation of
marrow occurred, and no evidence of cartilaginous tissue
was reported to be found in any of the grafts (Ohgushi
and Okumura, 1990, Haynesworth et al., 1992; Gundle et
al., 1995; Martin et al., 1997) Systematic studies that used
various transplantation vehicles demonstrated that
human BMSCs are more dependent on the nature of the
vehicles than are mouse BMSCs Human BMSCs consis-
tently form bone in vehicles containing HA/TCP ceramics
in the form of blocks, powder, or Collagraft'm (mixture of
ceramic powder with bovine collagen type 1). With
HA/TCP powder and Collagraftl', more extensive bone
formation was observed than with HA/TCP blocks, and
even more bone was formed when powder particles were
held together with a secondary vehicle, such as a fibrin
clot. In collagen sponges, human BMSC formed bone
only sporadically and only after cultivation with dexa-
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Figure 3. Heterogeneity of the osteogenic capacity of clonally derived human bone marrow stromal cells demonstrated by in vivo trans-
plantation. Individual clones, arising from the proliferation of a single CFU-F, were isolated from low-density cultures of human bone mar-
row cell suspensions and expanded in culture in order to generate enough cells for transplantation. Cells were attached to ceramic parti-
cles or adsorbed to CollagrahfTM as vehicles (V), and transplanted subcutaneously into immunocompromised mice. Transplants were har-
vested 6 weeks later and histologically analyzed. In some clones, only fibrous tissue (F) was formed (a), while in other clones fibrous tis-
sue (F) along with low levels of bone (B) were formed (b). In other clones, larger amounts of bone were formed, but hematopoiesis was
absent (c). Approximately 24% of the clones formed bone and supported hematopoiesis (HP) (d, e). In some cases (e), the clone was entire-
ly equivalent to a multi-colony-derived strain (f) in the amount of bone and HP formed in the ossicle.
methasone. No bone formation was observed in tbe
polyvinyl sponges, poly(L-lactic acid), and human de-
mineralized bone matrix (Krebsbach et al., 1997).
Likewise, human BMSCs formed bone when transplant-
ed into HA cubes, and loose connective tissue when
transplanted into collagen sponges (Martin et al., 1997).
Transplants with extensive bone formation always
demonstrated abundant hematopoietic tissue located
close to the newly formed bone (Krebsbach et 6il., 1997,
Kuznetsov et al., 1997b). It should be noted that HA/TCP
blocks (cubes or disks) used in the majority of these
studies proved to be less satisfactory for transplantation
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of human BMSCs than either HA/TCP powder (with or
without secondary vehicle) or CollagraftTM. There is no
reliable way to load cells into ceramic blocks (Dennis et
al., 1992). Whatever method is used (negative pressure,
direct cell suction, etc.), only a small portion of the cell
suspension can find its way into the vehicle, mostly into
peripheral pores. As a consequence, bone formation is
usually limited to the periphery of the transplants.
Moreover, there is no simple way to determine how many
cells were actually loaded into the ceramic block.
Specially designed experiments with 3H-thymidine-
labeled cell quantitation have shown that between
45,000 and 65,000 cells are loaded per 27 mm3 block when
the cell suspension contains 5 x 106 cells/mL (Dennis et
al., 1992). In contrast, ceramic powder can be quantita-
tively loaded by slow rotation of the cell/vehicle mixture;
this method is based on the high adhesive properties of
BMSCs. As a result, more than 80% of total cells can be
loaded, cells are distributed more evenly throughout the
vehicle, and osteogenesis is more extensive (Krebsbach
et al., 1997). In transplants of human BMSCs in ceramic
powder, bone and hematopoietic tissue showed no signs
of degeneration or senescence for at least 45 weeks post-
transplantation (Kuznetsov et al., 1997b). Consequently,
the newly formed heterotopic bone and hematopoietic
microenvironment are self-maintained (Fig. 2).
In 4-8-week-old transplants of human BMSCs into
immunocompromised mice or rats, three different
human-specific antibodies reacted with osteocytes and
osteoblasts of the new bone, but not with surrounding
recipient tissues (Haynesworth et al., 1992; Krebsbach et
al., 1997; Martin et al., 1997). In transplants of human
BMSCs, cells of the new bone were immunodetected
with antibodies raised against human osteonectin and
expressed human-specific alu sequences for at least 45
weeks post-transplantation (Kuznetsov et al., 1997b).
These data indicate that, in heterotopic transplants of
human BMSCs into an open system, as in transplants of
rodent BMSCs, new bone maintains the donor origin. On
the contrary, hematopoietic cells associated with the
new bone are of recipient origin (Kuznetsov et al., 1997b).
(C) TRANSPLANTATION OF CLONAL BMSC STRAINS
As previously mentioned, when marrow cells are plated
at low cell densities, BMSCs grow as discrete colonies,
each formed by proliferation of a single CFU-F
(Friedenstein etal., 1978; Latsiniket al., 1986). The studies
reviewed above have used multi-colony-derived strains
consisting of descendants of multiple BMSC colonies-
i.e., many CFU-Fs. However, to analyze the natural het-
erogeneity of a CFU-F population, one must study
descendants of individual CFU-Fs. About 20% of the
colonies formed bone when individual colonies of
mouse or guinea pig BMSCs were transplanted
(Chailakhyan et al., 1978). When rabbit single-colony-
derived BMSC strains were transplanted into diffusion
chambers, either autogenously or into immunocompro-
mised mice, bone was formed by 48.3% (Gerasimov et al.,
1986; Friedenstein et al., 1987) and 36.8% of the strains
(Bennett et al., 1991), respectively.
Human single-colony-derived BMSC strains from
four donors were transplanted into immunodeficient
mice in HA/TCP powder and Collagraft. After eight weeks,
20 out of 34 strains (58.8%) formed bone, and the
remainder formed only fibrous tissue. Among the 20 pos-
itive strains, eight formed extensive bone accompanied
by hematopoietic tissue (23.5%), and 12 formed less
abundant bone without hematopoiesis (35.3%)
(Kuznetsov et al., 1997b) (Fig. 3). These data demonstrate
that individual CFU-Fs are capable of forming both bone
and a supportive hematopoietic microenvironment. They
also demonstrate that the CFU-F population is heteroge-
neous and that only a fraction of it consists of multipo-
tential cells that have the ability to differentiate sequen-
tially into several tissues, including bone and
hematopoiesis-supportive stroma with associated
adipocytes.
(VI) Factors Influencing Bone Formation
in Open System Transplants of BMSCs
Many of the factors that influence osteogenesis by
BMSCs have been discussed above and include the
species origin of BMSCs, the composition of the trans-
plantation vehicle, and the method by which cells are
loaded into the vehicle. It is likely, however, that several
other factors participate to accelerate or impede osteo-
genesis by transplanted BMSCs. Among these potential
modifiers are: (1) the optimum in vitro cell expansion con-
ditions, (2) the cell seeding density, and (3) the ideal
vehicle composition. Other factors-such as the cryo-
preservation of BMSCs before transplantation and the
origin of marrow (age and gender of donor, skeletal loca-
tion, method of marrow extraction)-show no obvious
correlation with frequency or extent of bone formation
(Goshima et al., 199 lb; Haynesworth et al., 1992; Bruder et
al., 1997a; Krebsbach et al., 1997). The number of in vitro
passages and population doublings of the BMSCs before
transplantation did not affect bone formation as long as
the cells retained their proliferative status. However,
mouse BMSCs of the 13th passage that had ceased to
proliferate in vitro did not form bone in vivo (Krebsbach et
al., 1997). Rat BMSCs formed bone for up to 18 passages.
However, osteogenesis was delayed and the rate of bone
formation declined with increasing passage number
(Goshima et al., 1991a). In an extensive in vitro study, it
was demonstrated that cultured BMSCs derived from
human iliac crest aspirates average about 38 population
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doublings before becoming senescent, and despite
reaching a point of senescence, the cells remained capa-
ble of osteogenesis (Bruder et al., 1997b).
To date, the dependence of in vivo bone formation on
the number of transplanted BMSCs has not been sys-
tematically studied. When mouse BMSCs are transplant-
ed under the kidney capsule in collagen sponges, ossi-
cles containing bone marrow are formed in most of the
transplants containing from 1 x 105 to 2 x 106 BMSCs, but
not in transplants containing fewer than 0.5 x 105 BMSCs
(Grosheva et al, 1981; Friedenstein et al., 1982). Only
those ceramics (27 mm3 cubes) that retain greater than 3
x 104 rat BMSCs per transplant consistently form bone
(Dennis et al., 1992; Dennis and Caplan, 1993). Cell num-
ber may not influence the extent of bone formation
throughout the range of 1.5 to 16 x 106 mouse or human
BMSCs per transplant (20-100 mm3 vehicle volume)
(Krebsbach et al., 1997). However, in light of the above-
mentioned studies, these transplants likely exceeded the
threshold necessary for osteogenesis. Thus, it is evident
that the minimum number of BMSCs necessary for bone
formation after implantation is yet to be determined.
Medium composition can also significantly affect
bone formation by transplanted BMSCs. Specifically,
selected lots of serum appear to be particularly impor-
tant for growth of BMSCs from rodent species; however,
the factors that are present in various amounts from one
lot of serum to another have not been delineated. For
mouse BMSCs, the presence of dexamethasone in cul-
ture medium did not influence the extent of bone forma-
tion (Krebsbach et al., 1997). Similar observations were
noted with human BMSCs transplanted into HA/TCP-
containing vehicles (Gundle et al., 1995; Krebsbach et al.,
1997; Kuznetsov et al., 1997b). However, human BMSCs
transplanted into diffusion chambers or collagen
sponges formed bone only after cultivation in medium
that included dexamethasone (Gundle et al., 1995;
Krebsbach et al., 1997). In addition, when low numbers of
human BMSCs were transplanted (2.5 x 105 per 64 mm3
HA ceramic cube), cultivation with dexamethasone
increased the extent of bone formation (Martin et al.,
1997). Rat BMSCs transplanted into coralline HA ceram-
ic cubes formed bone only after cultivation with dexa-
methasone (Yoshikawa et al., 1996a).
The effects of several growth factors on bone forma-
tion by transplanted BMSCs have also been studied.
PDGF-BB (5 ng/mL, present for 48 hrs before transplan-
tation) did not change the in vivo bone formation by rat
BMSCs, while TGF-3 decreased bone formation in 50% of
the experiments under similar conditions (Cassiede et al.,
1996). Six-day pretreatment with BMP-2 (50 ng/mL) did
not stimulate bone formation by rat BMSCs, while pre-
treatment with bFGF (2.5 ng/mL) enhanced bone forma-
tion, which was further enhanced by a combination of
bFGF with BMP-2 (Hanada et al., 1997). Human BMSCs
grown in the presence of FGF-2 (1 and 10 ng/mL) yielded
significantly greater bone formation than those grown
without it, while other growth factors, including PDGF,
EGF, IGF-1, TGF- 31, and GH, did not affect the extent of
bone formation (Martin et al., 1997).
(VIl) Potential Clinical Applications
(A) ORTHOTOPIC TRANSPLANTATION OF BMSCs
Reconstruction of defective bone by means of graft mate-
rial, composed of mixtures of autogenous marrow and a
variety of different vehicles, is a widely used procedure in
orthopedics and oral surgery, the goal of which is to
restore the functional integrity of bone. Bone grafting is
a dynamic phenomenon: A successful graft heals,
becomes incorporated, revascularizes, and eventually
assumes the desired form and function. The ideal graft-
ing material fulfills three physiologic functions: First, it
provides a source of bone-forming cells; second, it
induces cells (either grafted or indigenous) to form bone,
a process called osteoinduction; and finally, it provides a
scaffold for new bone deposition, a process known as
osteoconduction.
(B) ANIMAL STUDIES
Determining the requirements for ectopic osteogenesis
in in vivo transplants of BMSCs is an important first step
in understanding how these populations of cells may be
used for future regenerative therapies. However, the
microenvironment of a subcutaneous implant site is far
different from that of a skeletal site in need of bone
regeneration. There are few studies that have investigat-
ed the regenerative potential of BMSCs in orthotopic
transplants, that is, in skeletal defects. In orthotopic con-
ditions, the differentiation of transplanted BMSCs is
influenced by both the transplantation site and vehicle
composition. Mouse BMSCs transplanted via collagen
sponges into a 5-mm calvarial defect formed bone as
early as two weeks post-transplantation. At 4-5 weeks,
the new bone completely covered the defect and could
be distinguished from pre-existing bone by a large cavity
filled with hematopoietic marrow. When transplanted
BMSCs were derived from transgenic mice harboring a
collagen type I-CAT transgene, cells of the new bone were
positive for CAT, thus demonstrating donor origin of the
new bone. The defect remained unhealed if empty vehi-
cles or vehicles filled with mouse spleen stromal cells
were transplanted (Mankani et al., 1 997a; Krebsbach et al.,
1998).
Autogenous rabbit BMSCs dispersed in a bovine
type I collagen gel have been transplanted into a large (3
x 6 mm), full-thickness defect in the weight-bearing sur-
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face of the medial femoral condyle. As early as two weeks
post-transplantation, the transplanted cells differentiat-
ed into chondrocytes in the upper half of the defect; the
deeper half was filled with newly formed cancellous
bone. At 24 weeks, the subchondral bone was complete-
ly repaired, without loss of overlying articular cartilage.
The cartilage surface remained smooth, although the car-
tilage became thin. In cell-free controls, there was sub-
stantially less repair. Mechanically, the reparative tissue
was stiffer than in cell-free controls, but less stiff than
normal cartilage (Wakitani et al., 1994).
Autogenous canine BMSCs were loaded into
fibronectin-coated HA/TCP cylinders and transplanted
into 21-mm-long segmental femoral mid-diaphyseal
defects. Rapid bone formation occurred at all host-
implant interfaces, resulting in union of all animals by
eight weeks. A substantial collar of bone developed sur-
rounding the implant itself; after 12 weeks, the callus
began to remodel to the original dimension of the
implant. Animals whose defects were not filled formed a
fibrous non-union. If cell-free vehicles were implanted,
bony ingrowth was limited to the interface, and the bulk
of the implant was devoid of bone. Cancellous bone from
the iliac crest was also transplanted to some defects;
these transplants were radiographically equivalent to the
BMSC-based ones (Bruder et al., 1998b,c).
(C) HUMAN STUDIES
In humans, blood and bone marrow are the most fre-
quently transplanted materials (Allard et al., 1987;
Pedrosa et at., 1989; Aglietti et al., 1991; Eggers and
Meeder, 1994; Friend et al., 1995; Olsen et al., 1995;
Arrington et al., 1996; Bradbury et al., 1996). Fresh autoge-
nous bone grafts are preferred in orthotopic procedures
because of their compatibility and efficacy. In addition,
autogenous grafts are able to trigger direct osteogenesis
by bone cells. Autogenous iliac bone is considered to
have the highest osteogenic potential, and indeed, the
osteogenic potential has been shown to reside within
the marrow stromal compartment. This is supported by
the clinical observation that autogenous bone impreg-
nated with red marrow has a beneficial effect on osteo-
genesis. However, the amount and quality of implanted
bone needed limit the use of autogenous bone alone.
Large defects may require a larger amount of bone than
is available for harvesting (Arrington et at., 1996). In addi-
tion, if the quality of bone is poor, such as in certain dis-
ease states, the autogenous bone may not be appropri-
ate for engraftment. These limitations point to the real
need for the development of procedures that use ex vivo
expanded BMSCs.
Experiments where human BMSCs are transplanted
orthotopically into animal recipients represent an inter-
mediate step between ectopic animal transplantation
and orthotopic transplantation into human patients.
Human BMSCs of the 2nd passage were loaded into
fibronectin-coated HA/TCP cylinders and transplanted
into 8 mm central diaphyseal defects of athymic rats. By
12 weeks, 47% of implant volume was filled with bone of
human origin; control transplants of empty vehicles con-
tained 27% bone. Also, stiffness and failure load of
BMSC-loaded implants was significantly greater than
those of cell-free implants (Bruder et al., 1997c, 1998c).
There are currently few studies that have attempted
the clinical use of ex vivo expanded human BMSCs.
Autogenous human BMSCs of various passages have
been loaded into demineralized allogenic cancellous
bone matrix and transplanted into long-lasting bone
defects of 20 patients. In these studies, there were seven
patients with non-union fractures, eight with
pseudoarthroses, and five with long bone defects.
Results from 15 patients were followed for up to two
years. All 15 patients demonstrated union and filling of
the defects, which was considerably faster and more effi-
cient than following other treatments (Osepjan et at.,
1987). Composite grafts of fresh autogenous marrow, cul-
tured autogenous BMSCs, and allogeneic lyophilized
bone fragments have also been transplanted into
mandibular defects immediately after surgery. After one
month, bone defects showed significant bone ingrowth;
after three months, they were completely filled with well-
mineralized bone in most patients. In control patients
transplanted with marrow cells plus bone fragments,
results were similar but were delayed by approximately
three months. In historical controls where no transplan-
tation had been performed, the healing was even slower,
and sometimes incomplete by 12 months (Krzymanski
and Wiktor-ledrzejczak, 1996).
(D) VASCULARIZED BONE GRAFTS
There are a number of clinical situations in which the
recipient site may not be amenable to direct transplan-
tation of BMSCs in combination with appropriate vehi-
cles, and bone healing may not be optimal. For example,
following high-dose radiation prior to surgery for the
removal of cancerous tissue, or in cases of persistent
deep infections, the recipient site can display a high
degree of morbidity and compromised vascularization.
This site morbidity may have a profound influence on the
rate at which transplants integrate, and may ultimately
lead to transplant failure. For this reason, the use of vas-
cularized bone grafts has been developed whereby seg-
ments of normal bone with intact vasculature are
removed from a donor site and placed into a morbid
recipient site to establish anastomosis with intact vascu-
lature at the margins (Storm et at., 1996).
A preliminary study in mice has shown that ex vivo
expanded BMSCs can be used to generate bone sur-
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rounding an isolated artery and vein. BMSCs in vehicle
were wrapped around the internal carotid artery and infe-
rior jugular vein, and further encircled with an expanded
polytetrafluoroethylene membrane (GoretexTM) to pre-
vent collateral vascularization. After eight weeks, the
transplant contained cortical and cancellous bone fully
perfused by the artery and vein. This technique shows a
great deal of promise for reconstructive surgery such that
a vascularized bone graft can be generated within the
patient's own body and then relocated to a recipient site
as needed (Mankani et al., 1997b).
(E) SYSTEMIC DISTRIBUTION OF BMSCS
The methodologies described above are very applicable
to the restoration of segmental bone defects. However, in
cases of generalized bone loss such as in a variety of
skeletal diseases including osteoporosis, osteogenesis
imperfecta, etc., it is not feasible to consider direct trans-
plantation into all affected bones. In these cases, it
would be desirable to inject BMSCs for distribution via
the circulatory system such that they would be widely
dispersed, and stimulated in some fashion to regenerate
new (and/or better) bone.
Injection of marrow stromal cells has been attempt-
ed in both animal models and in humans, with limited
success. There are numerous reports that stromal cells
present in the cell population injected during bone mar-
row transplantation procedures do not survive their trav-
els in the circulation, and do not repopulate bone or any
other tissue (Friedenstein and Kuralesova, 1971;
Friedenstein et al., 1978; Wilson et al., 1978; Golde et al.,
1980; Chertkov et al., 1985; Laver et al., 1987; Ma et al.,
1987; Simmons et al., 1987; Raskind et al., 1988;
Athanasou et al, 1990; Ribera et al., 1990; Agematsu and
Nakahori, 1991; Santucci etal., 1992). However, when par-
tially purified bone marrow stromal cells isolated from
transgenic mice expressing a human mini-gene for colla-
gen type I as a marker were injected into irradiated mice,
polymerase chain-reaction assays for the collagen mini-
gene indicated that, after 1-5 months, the donor cells
accounted for 1.5-12% of the cells in bone, cartilage, and
lung in addition to marrow and spleen (Pereira et al.,
1995). In other studies, an immortalized marrow stromal
cell line engineered to express ,B-galactosidase was also
found in bone after injection (Dahir et al., 1996). These
results suggest that BMSCs expanded in culture may
serve as long-lasting precursors of bone, cartilage, and
lung. However, it should be noted that in the first study,
the marrow stromal cells were likely contaminated with
macrophages which may engraft easily, and in the sec-
ond case, the cells used were immortalized, which may
represent a selective advantage to survival in the circula-
tory system compared with non-immortalized, normal
cells. In a recent report, Pereira and colleagues showed
that infusion of marrow stromal cells from wild-type
mice could partially rescue a phenotype of fragile bones
resembling osteogenesis imperfecta (Pereira et al., 1998).
DNA from the donor marrow stromal cells was detected
consistently in marrow, bone, cartilage, and lung either
one or 2.5 months after the infusions, suggesting that
marrow stromal cells or related cells in marrow may
serve as a source for continual renewal of cells in a num-
ber of nonhematopoietic tissues.
The route of injection may also influence the survival
of injected BMSCs (Mankani et al., 1997b). If injected via
the tail vein, BMSCs were removed primarily by the
lungs, and if injected via the left ventricle, the distribu-
tion was somewhat broader but still did not result in
localization of the BMSCs to bone or bone marrow. Only
when the cells were injected into the abdominal carotid
arteries were significant levels of BMSCs identified in
bone marrow, in addition to skin, muscle, and spleen.
However, it has not yet been demonstrated that these
cells survive long term and actually engraft.
Several human patients have been transfused with ex
vivo expanded BMSCs (Lazarus et al., 1995), although the
results concerning engraftment of these cells within
these patients are not yet available. Taken together, the
results of these experiments indicate that the dissemi-
nation of BMSCs via systemic injection is not routine,
and to date, specific homing of BMSCs to bone has not
been achieved by means of either normal or immortal-
ized cell lines. From these studies, it appears that it may
be necessary to provide BMSCs with a homing device-
e.g., a cell-surface molecule that would enable to BMSCs
to remain resident within the bone marrow, either
through transient or stable genetic engineering, or
through the treatment of the cells with factors that will
enable them to produce the required molecules.
(F) BMSCS AND GENE THERAPY
Based on the fact that transplanted BMSCs form a stable
ossicle containing bone and stromal cells of donor origin
that is self-maintained for long periods of time, BMSCs
appear to be good candidates for gene therapy. During ex
vitro expansion, BMSCs may be genetically manipulated
to produce a desired cellular product. Generation of an
ectopic bone ossicle or pedicled bone graft in a subcuta-
neous site by means of engineered BMSCs could be envi-
sioned as an in vivo "mini-pump", generating the desired
factor and releasing it into the circulation. Such an
ectopic ossicle would have the advantage of allowing for
easy removal should the "therapy" supplied by the ossi-
cle no longer be required. Furthermore, new methods are
being developed to correct genetic mutations by a num-
ber of strategies including hammerhead ribozymes
(Sakai et al., 1996; Grassi et al., 1997). It can be envisioned
that autogenous BMSCs could be engineered to correct a
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defective gene and be systemically distributed (when
conditions for this procedure have been established) in
order to re-establish a normal bone/marrow microenvi-
ronment.
Currently, there is a variety of methods that utilize
either retroviral or adenoviral vectors that mediate stable
or transient transfection of a target cell population.
While the success of these types of transfections is rou-
tine in vitro, reports of their successful utilization in vivo to
bring about gene transfer has been sporadic at best.
Recently, it has been demonstrated that normal human
BMSCs can be transfected with adenovirus coupled to 1-
galactosidase as a marker (MF Young, unpublished
results). Furthermore, transplants made by cells express-
ing lacZ and IL-3 have been generated, and IL-3 was
detected in the circulation of the animals for up to 12
weeks after transplantation (Allay et al., 1997).
(G) ANIMAL MODELS OF HUMAN BONE DISORDERS
The observation that BMSCs are osteogenic precursors
capable of recreating the architecture of their original tis-
sue gave rise to the hypothesis that transplanted BMSCs
may recapitulate the pathophysiology of skeletal dis-
ease, thus creating an in vivo model of skeletal disorders.
So far, this assumption has been proved true for the
McCune-Albright Syndrome (MAS). McCune-Albright
Syndrome is a non-inherited genetic disease caused by
activating missense mutations of the gene encoding the
cx subunit of the stimulating G protein. MAS is a mosaic
disorder whose manifestations include endo-
crinopathies, skin hyperpigmentation, and polyostotic
fibrous dysplasia of bone. When BMSC colonies from
MAS patients were cultured, they were found to be of two
types: normal (cells contained two normal Gsx alleles)
and mutant (one normal allele and one with mutation).
Subcutaneous transplantation of normal BMSCs into
immunocompromised mice resulted in the formation of
normal ossicles, while transplantation of mutant cells
alone led to the loss of transplanted cells with no ossicle
formation. However, transplantation of a mixture of nor-
mal and mutant cells reproduced an abnormal ectopic
ossicle recapitulating many features of human fibrous
dysplasia (Bianco et al., 1998). These data provide addi-
tional insight into the pathophysiology of fibrous dys-
plasia in MAS and offer a novel approach to the study of
the disease and potential therapeutic interventions.
More generally, transplantation of pathologic BMSCs in
vivo may provide a promising strategy for generating
animal models of other human bone disorders.
(Vill) Future Directions
While our understanding of the nature of BMSCs has
been greatly expanded during recent years, it is clear that
there is still much to be learned about these important
mediators of skeletal metabolism, and that their further
characterization is crucial for their clinical application.
Questions that remain unanswered include: (1) What is
the in vivo identity of the CFU-F, the progeny of which we
have partially characterized as BMSCs in vitro? (2) How do
CFU-F and their progeny participate in the processes of
normal skeletal metabolism, and how are these process-
es changed in disease states? and (3) What are the regu-
latory factors that influence the activity of CFU-F and
their progeny to determine which phenotype they will
express, both in vivo and in vitro?
If these questions are to be answered, it is clear that
better identification of CFU-Fs and BMSCs must be
made, both in vivo and in vitro. To date, there is only a
handful of markers (as identified by monoclonal anti-
bodies) that appear to be specific for these cells (Akasaka
et al., 1991; Simmons and Torok-Storb, 1991; Benayahu et
al., 1995; Masuhara et al., 1995; Bruder et al., 1997a). For
the most part, the antigens recognized by these antibod-
ies have not been well-characterized, and their absolute
specificity is not clear. A recent discovery that may assist
in the purification of "potential stem cells" within the
BMSC population is the finding that a monoclonal anti-
body (SB-10) recognizes the activated leukocyte-cell
adhesion molecule (ALCAM) (Bruder et al., 1998a).
Because ALCAM is expressed on human BMSCs but is
lost during developmental progression into differentiat-
ed tissues, SB-10 will likely be an important experimen-
tal tool for the study of osteoblast cell lineage. Through
the use of new molecular biological technologies-such
as subtractive hybridizations, differential display, SAGE
(serial analysis of gene expression), and microarray tech-
nologies-it is hoped that new genes that are uniquely
expressed by these cells will be identified. At the very
least, should unique markers remain elusive, a pattern of
gene expression, a so-called "fingerprint", will be gener-
ated through these types of analyses. With this informa-
tion, development of reagents and screening strategies
would allow for the identification of stem cells in vivo and
the potential for cell sorting and further analysis in vitro.
A major gap in our knowledge relates to the fact that
the true "stem-cell" character of BMSCs (i.e., continuous
self-renewal) has not been definitively proven in any ani-
mal species. If there is a true "stem-cell" present in this
population, it will be necessary to determine the appro-
priate ex vivo culture conditions that will maintain their
stem cell character (as has been done for embryonic
stem cells used in the generation of transgenic animals),
and then to induce them to differentiate into the desired
phenotype through the modulation of their microenvi-
ronment, both in vivo and in vitro. Consequently, a better
understanding of the hierarchy of CFU-Fs and BMSCs is
needed. While it is now recognized that these popula-
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tions display a variety of phenotypic expression patterns
(osteoblastic, chondrogenic, hematopoiesis-supportive,
adipocytic) both in vivo and in vitro, it is not understood
how this phenotypic heterogeneity is established, main-
tained, and disrupted in disease states.
Animal studies have provided a great deal of encour-
agement; however, there are several obstacles that must
be overcome prior to the use of BMSCs in human clinical
protocols. First, large quantities of ex vivo expanded cells
must be generated in an FDA-approved tissue culture
facility in order to provide enough material for recon-
struction of typically large skeletal segmental defects.
True utility of BMSCs in skeletal regeneration will require
major improvements in the current ex vivo expansion pro-
cedures to increase the yield and reduce the time
required to generate sufficient numbers of cells. Given
the inherent heterogeneity of the BMSC population, it
may also be required to develop large-scale cloning pro-
cedures such that clones with desired phenotypic char-
acteristics can be purified and used directly in tissue
engineering protocols. For example, in the regeneration
of craniofacial bones, which are primarily devoid of
hematopoietic marrow, BMSCs clones that give rise only
to bone without hematopoiesis would be more desirable
than the use of multi-colony-derived strains that would
generate bone along with hematopoietic stroma.
Second, there is a need for continued development
of vehicles for the introduction and engraftment of these
cells in vivo. Appropriate vehicles must be engineered and
carefully selected depending on the site to be recon-
structed (weight-bearing vs. non-weight-bearing sites,
trabecular vs. cortical sites, etc.). It is likely that recon-
struction of a particular skeletal site will require different
vehicles, with or without bioactive factors, designed to
direct the activity of BMSCs into specific expression pat-
terns to regenerate bone in the desired shape and form.
Finally, if the use of BMSCs in gene therapy proto-
cols is to be successful, better methods for stably or tran-
siently transfecting normal human cells with high effi-
ciency are critical. It can be envisioned that BMSCs can
be either transiently or stably transfected to produce a
protein that is missing or defective, and implanted with-
in a patient to provide a missing or defective protein.
However, expression of the desired protein product must
be controlled such that the level of its production, post-
translational modification, secretion, and localization to
the desired active site is suitable. Selection of the appro-
priate promoter driving the ectopic production of the
desired protein is of critical importance for physiologi-
cally significant expression and secretion and will
require extensive knowledge of gene expression patterns
on the part of the implant team.
While it is clear that there is much yet to be learned,
it is also clear that the BMSC population provides a
unique scientific opportunity for us not only to better our
understanding of the processes of skeletal metabolism
and homeostasis, but also to translate this information
into clinical procedures that will provide a great deal of
patient benefit.
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